article “The first thing we want to do is take the DNA of the person we want, and then use that DNA to make a new DNA, and that new DNA is in turn used to make the next generation of the organism,” Dr. V. J. Shah said in a phone interview.
“The next generation is going to be that we can actually grow the organism.
That’s the way we want it to be.
So, we’re trying to develop an alternative DNA technology, and I think it’s a very exciting opportunity.”
The company’s goal is to begin testing a variety of products on the market soon, including drugs for treating diseases like cancer, and even the production of personalized medicine.
Its focus on using DNA to synthesize medicines has been applauded by many scientists and biotech executives.
“It’s not just about making drugs,” Shah said.
“That’s a huge step forward.
The idea of taking the DNA from the patient, putting it into a pill, and using that pill to make medicine is really exciting.”
Dr. V J. Travan, the co-founder of the company, said the company’s first drug, named Jumia, will target pancreatic cancer, heart disease, and other diseases.
Dr. T. A. Shroff, the company CEO, said Jumio is also being developed to treat cancer of the lungs, liver, spleen, and kidneys.
Jumias goal is also to provide a way to generate genetic material for human gene therapy.
“There are two different kinds of genome, and we want people to be able to do the right thing,” Shah explained.
“So, if you have a cancer gene, if we can make that gene, that will be the first and only cure for that disease.”
Dr Shah and Shroiff said they were particularly interested in a drug for Alzheimer’s.
“We’re in a time when Alzheimer’s is really being diagnosed in the United States, and the diagnosis is a very complicated disease, so we wanted to understand if we could get a gene that could be a gene therapy for Alzheimer,” Shah told Ars.
“We are going to look at that as well as how we can take the patient gene and produce a drug that can also be used to treat Alzheimer’s.”
Jumia’s first patent is scheduled for approval in the next two years.
If approved, the drug would be the companys first treatment for Alzheimer disease.
If the drug does not work, the therapy could still work, Shah said, but it could be as long as 10 years before the drug was effective.
The company plans to use a third of its revenues to support the research of Jumiatry’s DNA technology.